Guerbet : CA T2 supérieur aux attentes – Guidances confirmées – Les risques autour de Dotarem n’ont néanmoins pas disparu
>CA T2 2018 meilleur qu’attendu malgré le FX - Les ventes du T2 2018 ont progressé de 1,2% (-1,2%e à tcc).A fin juin, le CA ressort à 389,6 M€, en repli de 4,3%, impacté par les changes (-26,1 M€, en particulier real et US$). A taux de changes constant, la progression serait de 2,1%. L’Europe baisse de 9,2%, (-7,5% à tcc) notamment en raison de l’arrivée du générique de Dotarem® sur la France et l’Allemagne, les deux principaux marchés. Le reste du monde est stab...Guerbet is a French pharmaceutical group that develops, markets, and provides maintenance services for medical equipment and devices destined for diagnostic and interventional imaging. Co.'s portfolio comprises media solutions covering MRI, X-rays and products devoted to International Radiology and Theranostics and medical devices. Co. organizes its operation by product family covering Magnetic Resonance Imaging (MRI), X-rays (XR) and Interventional Radiology and Theranostics (IRT). The MRI family includes Dotarem® and Artirem®; Co.'s X-ray product family includes Xenetix®, Optiray®/Optiject®, Oxilan®, and Telebrix®; and the IRT product family has Lipiodol®, Bleu Patente V and Hexabrix®.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.